JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Microvascular disease: what does the UKPDS tell us about diabetic retinopathy?

Background The UK Prospective Diabetes Study (UKPDS) was a randomised controlled clinical study which looked at the effect of improved blood glucose and blood pressure control on macro- and microvascular complications in Type 2 diabetes. Retinopathy was the commonest microvascular outcome and this paper looks at this complication. Methods Newly diagnosed diabetic patients were randomised to intensive or conventional glycaemic control and a subset of hypertensive patients to tight or less tight blood pressure control. Patients were seen every 3 months in study clinics and retinopathy was assessed by adjudicated grading of triennial colour retinal photographs. Photocoagulation treatment, vitreous haemorrhage and cataract extraction were predefined UKPDS endpoints. Observational analyses of the data were used to examine the relationship of updated mean glycated haemoglobin (HbA(1c)) and mean blood pressure levels to retinopathy outcomes. Results The UKPDS showed that both improved glucose control and improved blood pressure control reduced the risk of retinopathy, with a linear relationship between the log hazard ratio for retinopathy and both updated mean HbA(1c) and updated mean blood pressure. A 1% decrement in HbA(1c) equated to a 31% reduction in retinopathy and a 10 mmHg decrement in systolic blood pressure equated to an 11% reduction in photocoagulation or vitreous haemorrhage. Evidence of retinopathy at diagnosis, including the presence of microaneurysms only, increased significantly the risk of progression to photocoagulation. Conclusions The UKPDS stands out as a landmark study in Type 2 diabetes, emphasising the crucial importance of controlling both blood glucose and blood pressure in order to minimise the risk of developing sight-threatening retinopathy.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app